MétaCan
Menu
← Back to cohort

A Cost-Utility Analysis of Smoking Cessation Programs for Patients with Crohnʼs Disease

2013· article· en· W2978831891 on OpenAlexaffabout
Stephanie Coward, Steven J. Heitman, Fiona Clement, María E. Negrón, Remo Panaccione, Subrata Ghosh, Herman W. Barkema, Cynthia Seow, Yvette Leung, Gilaad G. Kaplan

Bibliographic record

VenueThe American Journal of Gastroenterology · 2013
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsUniversity of Calgary
Fundersnot available
KeywordsMedicineSmoking cessationVareniclineQuality-adjusted life yearNicotine replacement therapyCohortAzathioprineCost effectivenessPhysical therapyDiseaseInternal medicineEmergency medicine

Abstract

fetched live from OpenAlex

Purpose: Smoking worsens the prognosis of Crohn's disease (CD) by increasing the risk of flaring and surgery; however, smoking cessation programs for CD patients are lacking. Studies evaluating the costs and benefits of introducing a smoking cessation program for CD patients are needed. We assessed the cost-utility of implementing various smoking cessation programs among patients with CD. Methods: TreeAge Pro 2012 was used to create a cost-utility analysis using a Markov model from the perspective of a publicly funded health care system. The base case was a 35-year old smoker with CD in remission on azathioprine. In addition to no program, four smoking cessation strategies were evaluated over a 5-year time horizon: nicotine replacement therapy (NRT), counseling, NRT + counseling, and varenicline (Champix). Health states accounted for disease remission and flares. Patients were on medical therapy (azathioprine or an anti-TNF), had anti-TNF dose escalations, switched to a 2nd anti-TNF, had surgery, or died. The measure of effectiveness was quality-adjusted life-years (QALYs) gained. Direct costs in Canadian dollars were estimated for smoking cessation programs, medications, and surgery. Utilities were derived from the IBD literature. Analyses were performed using Markov cohort simulation with second-order Monte Carlo simulation, used to derive means and 95% confidence intervals (CI). Threshold and probabilistic sensitivity analyses were done. Results: All smoking cessation programs were less costly and more effective than no program. The most cost-effective strategy was varenicline, at $45,653 (95% CI $43,445-$47,862) per patient over 5 years. Prescribing varenicline saved $4,000 per patient when compared to no program. The remaining strategies from most to least cost-effective were NRT + counseling, NRT, and counseling. A threshold analysis demonstrated that no program was the least costly approach only when the other smoking cessation strategies cost over 10 times their modeled cost. Conclusion: Over a 5-year period, all smoking cessation strategies were cost-saving and at least as effective for CD patients compared to the most common current strategy of no program. These cost savings and benefits are in addition to the other positive effects of smoking cessation. Healthcare systems should urgently invest in smoking cessation programs targeted at CD patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.014
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.032
Threshold uncertainty score0.063

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.014
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.003
Bibliometrics0.0020.002
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.239
Teacher spread0.231 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2013
Admission routes2
Has abstractyes

Explore more

Same venueThe American Journal of Gastroenterology→Same topicInflammatory Bowel Disease→French-language works237,207→